Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 26, 2025
Язык: Английский
Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 26, 2025
Язык: Английский
Pharmacology Research & Perspectives, Год журнала: 2025, Номер 13(2)
Опубликована: Фев. 25, 2025
ABSTRACT Epilepsy, a chronic neurological disorder affecting around 65 million people globally, is characterized by recurrent, unprovoked epileptic seizures. Psilocin, the active metabolite of psilocybin, well‐known psychedelic compound, has recently gained attention for its potential antidepressant and anxiolytic properties. This study aims to investigate anticonvulsant effects psilocin. The utilizes behavioral seizure models electrophysiological recordings in mice assess efficacy pentylenetetrazole (PTZ) test clonic seizures maximal electroshock ( MES ) generalized tonic–clonic are employed. Cortical electrical activity monitored provide insights into compound's on neuronal activity. involvement kynurenine pathway, opioidergic nitrergic systems, as well cannabinoid receptors using agonist/antagonist paradigms. Western blotting was employed evaluate expression levels key enzymes implicated psilocin's effects. findings indicate possible modulation psilocin, with modest doses (3 mg/kg, i.p.) demonstrating Remarkably, administration 1‐ MT , L‐ NAME naltrexone, sildenafil, AM ‐251 led diminishment underscoring cGMP CB1 receptor mediating respectively. Based western analysis, upregulation 5‐ HT1A but not HT2A downregulation IDO following psilocin were observed. Acute exerts that might be mediated at least part through opioidergic, serotonergic, systems.
Язык: Английский
Процитировано
1International Immunopharmacology, Год журнала: 2025, Номер 153, С. 114304 - 114304
Опубликована: Март 20, 2025
Язык: Английский
Процитировано
1Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 26, 2025
Язык: Английский
Процитировано
0